Advertisement

Parvovirus B19

  • Morgan HakkiEmail author
  • Lynne Strasfeld
Chapter

Abstract

Parvovirus B19 was discovered in 1975, and the first reports associating B19 with human disease came 6 years later, when B19 was linked to cases of aplastic crisis in patients with sickle cell disease. Since then, B19 infection has become a recognized infectious complication in the immunocompromised host, including persons infected with human immunodeficiency virus (HIV), as well as solid organ (SOT) and hematopoietic cell transplant (HCT) recipients. While typically a benign, self-limited infection in immunocompetent hosts, B19 can have serious sequelae in the immunocompromised host. Fundamentals of disease pathogenesis, clinical manifestations, diagnosis, and treatment options are discussed.

Keywords

Parvovirus B19, Solid organ transplant, Hematopoietic cell transplant, Virus 

References

  1. 1.
    Berns K, Parrish CR. Parvoviridae. In: Knipe DM, Howley PM, editors. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 2437–77.Google Scholar
  2. 2.
    Candotti D, Etiz N, Parsyan A, Allain JP. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol. 2004;78(22):12169–78.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Hokynar K, Soderlund-Venermo M, Pesonen M, Ranki A, Kiviluoto O, Partio EK, et al. A new parvovirus genotype persistent in human skin. Virology. 2002;302(2):224–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Nguyen QT, Wong S, Heegaard ED, Brown KE. Identification and characterization of a second novel human erythrovirus variant, A6. Virology. 2002;301(2):374–80.PubMedCrossRefGoogle Scholar
  5. 5.
    Servant A, Laperche S, Lallemand F, Marinho V, De Saint Maur G, Meritet JF, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol. 2002;76(18):9124–34.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Gallinella G, Venturoli S, Manaresi E, Musiani M, Zerbini M. B19 virus genome diversity: epidemiological and clinical correlations. J Clin Virol. 2003;28(1):1–13.PubMedCrossRefGoogle Scholar
  7. 7.
    Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet. 1975;1(7898):72–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Pattison JR, Jones SE, Hodgson J, Davis LR, White JM, Stroud CE, et al. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet. 1981;1(8221):664–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Serjeant GR, Topley JM, Mason K, Serjeant BE, Pattison JR, Jones SE, et al. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet. 1981;2(8247):595–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Neild G, Anderson M, Hawes S, Colvin BT. Parvovirus infection after renal transplant. Lancet. 1986;2(8517):1226–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Ozawa K, Kurtzman G, Young N. Replication of the B19 parvovirus in human bone marrow cell cultures. Science. 1986;233(4766):883–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Blundell MC, Beard C, Astell CR. In vitro identification of a B19 parvovirus promoter. Virology. 1987;157(2):534–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Ozawa K, Ayub J, Hao YS, Kurtzman G, Shimada T, Young N. Novel transcription map for the B19 (human) pathogenic parvovirus. J Virol. 1987;61(8):2395–406.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Cotmore SF, McKie VC, Anderson LJ, Astell CR, Tattersall P. Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. J Virol. 1986;60(2):548–57.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Ozawa K, Young N. Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J Virol. 1987;61(8):2627–30.PubMedPubMedCentralGoogle Scholar
  16. 16.
    St Amand J, Beard C, Humphries K, Astell CR. Analysis of splice junctions and in vitro and in vivo translation potential of the small, abundant B19 parvovirus RNAs. Virology. 1991;183(1):133–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Brown KE, Young NS, Liu JM. Molecular, cellular and clinical aspects of parvovirus B19 infection. Crit Rev Oncol Hematol. 1994;16(1):1–31.PubMedCrossRefGoogle Scholar
  18. 18.
    Doerig C, Hirt B, Antonietti JP, Beard P. Nonstructural protein of parvoviruses B19 and minute virus of mice controls transcription. J Virol. 1990;64(1):387–96.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Raab U, Beckenlehner K, Lowin T, Niller HH, Doyle S, Modrow S. NS1 protein of parvovirus B19 interacts directly with DNA sequences of the p6 promoter and with the cellular transcription factors Sp1/Sp3. Virology. 2002;293(1):86–93.PubMedCrossRefGoogle Scholar
  20. 20.
    Momoeda M, Wong S, Kawase M, Young NS, Kajigaya S. A putative nucleoside triphosphate-binding domain in the nonstructural protein of B19 parvovirus is required for cytotoxicity. J Virol. 1994;68(12):8443–6.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol. 1998;72(4):3018–28.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Sol N, Le Junter J, Vassias I, Freyssinier JM, Thomas A, Prigent AF, et al. Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J Virol. 1999;73(10):8762–70.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Morita E, Nakashima A, Asao H, Sato H, Sugamura K. Human parvovirus B19 nonstructural protein (NS1) induces cell cycle arrest at G(1) phase. J Virol. 2003;77(5):2915–21.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Morita E, Tada K, Chisaka H, Asao H, Sato H, Yaegashi N, et al. Human parvovirus B19 induces cell cycle arrest at G(2) phase with accumulation of mitotic cyclins. J Virol. 2001;75(16):7555–63.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Wan Z, Zhi N, Wong S, Keyvanfar K, Liu D, Raghavachari N, et al. Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2F family of transcription factors. J Clin Invest. 2010;120(10):3530–44.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science. 1993;262(5130):114–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Kawase M, Momoeda M, Young NS, Kajigaya S. Most of the VP1 unique region of B19 parvovirus is on the capsid surface. Virology. 1995;211(2):359–66.PubMedCrossRefGoogle Scholar
  28. 28.
    Rosenfeld SJ, Yoshimoto K, Kajigaya S, Anderson S, Young NS, Field A, et al. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest. 1992;89(6):2023–9.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Saikawa T, Anderson S, Momoeda M, Kajigaya S, Young NS. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol. 1993;67(6):3004–9.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Dorsch S, Liebisch G, Kaufmann B, von Landenberg P, Hoffmann JH, Drobnik W, et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol. 2002;76(4):2014–8.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Filippone C, Zhi N, Wong S, Lu J, Kajigaya S, Gallinella G, et al. VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology. 2008;374(2):444–52.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Luo W, Astell CR. A novel protein encoded by small RNAs of parvovirus B19. Virology. 1993;195(2):448–55.PubMedCrossRefGoogle Scholar
  33. 33.
    St Amand J, Astell CR. Identification and characterization of a family of 11-kDa proteins encoded by the human parvovirus B19. Virology. 1993;192(1):121–31.PubMedCrossRefGoogle Scholar
  34. 34.
    Chen AY, Zhang EY, Guan W, Cheng F, Kleiboeker S, Yankee TM, et al. The small 11 kDa nonstructural protein of human parvovirus B19 plays a key role in inducing apoptosis during B19 virus infection of primary erythroid progenitor cells. Blood. 2010;115(5):1070–80.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Zhi N, Mills IP, Lu J, Wong S, Filippone C, Brown KE. Molecular and functional analyses of a human parvovirus B19 infectious clone demonstrates essential roles for NS1, VP1, and the 11-kilodalton protein in virus replication and infectivity. J Virol. 2006;80(12):5941–50.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Ozawa K, Kurtzman G, Young N. Productive infection by B19 parvovirus of human erythroid bone marrow cells in vitro. Blood. 1987;70(2):384–91.PubMedGoogle Scholar
  37. 37.
    Leruez M, Pallier C, Vassias I, Elouet JF, Romeo P, Morinet F. Differential transcription, without replication, of non-structural and structural genes of human parvovirus B19 in the UT7/EPO cell as demonstrated by in situ hybridization. J Gen Virol. 1994;75(Pt 6):1475–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Miyagawa E, Yoshida T, Takahashi H, Yamaguchi K, Nagano T, Kiriyama Y, et al. Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity. J Virol Methods. 1999;83(1–2):45–54.PubMedCrossRefGoogle Scholar
  39. 39.
    Filippone C, Franssila R, Kumar A, Saikko L, Kovanen PE, Soderlund-Venermo M, et al. Erythroid progenitor cells expanded from peripheral blood without mobilization or preselection: molecular characteristics and functional competence. PLoS One. 2010;5(3):e9496.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Wong S, Zhi N, Filippone C, Keyvanfar K, Kajigaya S, Brown KE, et al. Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication. J Virol. 2008;82(5):2470–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, et al. Experimental parvoviral infection in humans. J Infect Dis. 1985;152(2):257–65.PubMedCrossRefGoogle Scholar
  42. 42.
    Lee TH, Kleinman SH, Wen L, Montalvo L, Todd DS, Wright DJ, et al. Distribution of parvovirus B19 DNA in blood compartments and persistence of virus in blood donors. Transfusion. 2011;51(9):1896–908.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Chipman PR, Agbandje-McKenna M, Kajigaya S, Brown KE, Young NS, Baker TS, et al. Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor. Proc Natl Acad Sci U S A. 1996;93(15):7502–6.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Weigel-Kelley KA, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol. 2001;75(9):4110–6.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Weigel-Kelley KA, Yoder MC, Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood. 2003;102(12):3927–33.PubMedCrossRefGoogle Scholar
  46. 46.
    Jordan JA, DeLoia JA. Globoside expression within the human placenta. Placenta. 1999;20(1):103–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Morey AL, Ferguson DJ, Fleming KA. Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in vitro: evidence of cell death by apoptosis. J Pathol. 1993;169(2):213–20.PubMedCrossRefGoogle Scholar
  48. 48.
    Brown KE, Young NS. Parvovirus B19 in human disease. Annu Rev Med. 1997;48:59–67.PubMedCrossRefGoogle Scholar
  49. 49.
    Manaresi E, Zuffi E, Gallinella G, Gentilomi G, Zerbini M, Musiani M. Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins. J Med Virol. 2001;64(1):67–73.PubMedCrossRefGoogle Scholar
  50. 50.
    Palmer P, Pallier C, Leruez-Ville M, Deplanche M, Morinet F. Antibody response to human parvovirus B19 in patients with primary infection by immunoblot assay with recombinant proteins. Clin Diagn Lab Immunol. 1996;3(2):236–8.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Kaikkonen L, Lankinen H, Harjunpaa I, Hokynar K, Soderlund-Venermo M, Oker-Blom C, et al. Acute-phase-specific heptapeptide epitope for diagnosis of parvovirus B19 infection. J Clin Microbiol. 1999;37(12):3952–6.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Kerr S, O'Keeffe G, Kilty C, Doyle S. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J Med Virol. 1999;57(2):179–85.PubMedCrossRefGoogle Scholar
  53. 53.
    Manaresi E, Gallinella G, Zerbini M, Venturoli S, Gentilomi G, Musiani M. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay. J Med Virol. 1999;57(2):174–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Soderlund M, Brown CS, Spaan WJ, Hedman L, Hedman K. Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19. J Infect Dis. 1995;172(6):1431–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol. 2004;53(Pt 6):459–75.PubMedCrossRefGoogle Scholar
  56. 56.
    Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350(6):586–97.PubMedCrossRefGoogle Scholar
  57. 57.
    Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin--a report of eight patients. Am J Hematol. 1999;61(1):16–20.PubMedCrossRefGoogle Scholar
  58. 58.
    Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med. 1989;321(8):519–23.PubMedCrossRefGoogle Scholar
  59. 59.
    Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Blaese RM, Young NS. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest. 1989;84(4):1114–23.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Schwarz TF, Roggendorf M, Hottentrager B, Modrow S, Deinhardt F, Middeldorp J. Immunoglobulins in the prophylaxis of parvovirus B19 infection. J Infect Dis. 1990;162(5):1214.PubMedCrossRefGoogle Scholar
  61. 61.
    Ballou WR, Reed JL, Noble W, Young NS, Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis. 2003;187(4):675–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Heegaard ED, Rasksen CJ, Christensen J. Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen. J Med Virol. 2002;67(3):375–83.PubMedCrossRefGoogle Scholar
  63. 63.
    Mitchell LA, Leong R, Rosenke KA. Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy? J Med Microbiol. 2001;50(7):627–35.PubMedCrossRefGoogle Scholar
  64. 64.
    Tolfvenstam T, Lundqvist A, Levi M, Wahren B, Broliden K. Mapping of B-cell epitopes on human parvovirus B19 non-structural and structural proteins. Vaccine. 2000;19(7–8):758–63.PubMedCrossRefGoogle Scholar
  65. 65.
    von Poblotzki A, Gigler A, Lang B, Wolf H, Modrow S. Antibodies to parvovirus B19 NS-1 protein in infected individuals. J Gen Virol. 1995;76(Pt 3):519–27.CrossRefGoogle Scholar
  66. 66.
    Corcoran A, Doyle S, Waldron D, Nicholson A, Mahon BP. Impaired gamma interferon responses against parvovirus B19 by recently infected children. J Virol. 2000;74(21):9903–10.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Isa A, Kasprowicz V, Norbeck O, Loughry A, Jeffery K, Broliden K, et al. Prolonged activation of virus-specific CD8+T cells after acute B19 infection. PLoS Med. 2005;2(12):e343.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Kasprowicz V, Isa A, Tolfvenstam T, Jeffery K, Bowness P, Klenerman P. Tracking of peptide-specific CD4+ T-cell responses after an acute resolving viral infection: a study of parvovirus B19. J Virol. 2006;80(22):11209–17.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Norbeck O, Isa A, Pohlmann C, Broliden K, Kasprowicz V, Bowness P, et al. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. J Virol. 2005;79(18):12117–21.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Tolfvenstam T, Oxenius A, Price DA, Shacklett BL, Spiegel HM, Hedman K, et al. Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19. J Virol. 2001;75(1):540–3.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    von Poblotzki A, Gerdes C, Reischl U, Wolf H, Modrow S. Lymphoproliferative responses after infection with human parvovirus B19. J Virol. 1996;70(10):7327–30.Google Scholar
  72. 72.
    Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol. 1988;25(2):151–3.PubMedCrossRefGoogle Scholar
  73. 73.
    Koch WC, Adler SP. Human parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J. 1989;8(2):83–7.PubMedGoogle Scholar
  74. 74.
    Chorba T, Coccia P, Holman RC, Tattersall P, Anderson LJ, Sudman J, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis. 1986;154(3):383–93.PubMedCrossRefGoogle Scholar
  75. 75.
    Plummer FA, Hammond GW, Forward K, Sekla L, Thompson LM, Jones SE, et al. An erythema infectiosum-like illness caused by human parvovirus infection. N Engl J Med. 1985;313(2):74–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Dowell SF, Torok TJ, Thorp JA, Hedrick J, Erdman DD, Zaki SR, et al. Parvovirus B19 infection in hospital workers: community or hospital acquisition? J Infect Dis. 1995;172(4):1076–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Gillespie SM, Cartter ML, Asch S, Rokos JB, Gary GW, Tsou CJ, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA. 1990;263(15):2061–5.PubMedCrossRefGoogle Scholar
  78. 78.
    Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev. 1999;13(3):194–204.PubMedCrossRefGoogle Scholar
  79. 79.
    Yu MY, Alter HJ, Virata-Theimer ML, Geng Y, Ma L, Schechterly CA, et al. Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion. 2010;50(8):1712–21.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Aubin JT, Defer C, Vidaud M, Maniez Montreuil M, Flan B. Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang. 2000;78(1):7–12.PubMedCrossRefGoogle Scholar
  81. 81.
    Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang. 1998;75(2):97–102.PubMedCrossRefGoogle Scholar
  82. 82.
    Kleinman SH, Glynn SA, Lee TH, Tobler L, Montalvo L, Todd D, et al. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion. 2007;47(10):1756–64.PubMedCrossRefGoogle Scholar
  83. 83.
    Parsyan A, Candotti D. Human erythrovirus B19 and blood transfusion - an update. Transfus Med. 2007;17(4):263–78.PubMedCrossRefGoogle Scholar
  84. 84.
    Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion. 2001;41(1):130–5.PubMedCrossRefGoogle Scholar
  85. 85.
    Yango A Jr, Morrissey P, Gohh R, Wahbeh A. Donor-transmitted parvovirus infection in a kidney transplant recipient presenting as pancytopenia and allograft dysfunction. Transpl Infect Dis. 2002;4(3):163–6.PubMedCrossRefGoogle Scholar
  86. 86.
    Zolnourian ZR, Curran MD, Rima BK, Coyle PV, O'Neill HJ, Middleton D. Parvovirus B19 in kidney transplant patients. Transplantation. 2000;69(10):2198–202.PubMedCrossRefGoogle Scholar
  87. 87.
    Hayakawa H, Tara M, Niina K, Osame M. A clinical study of adult human parvovirus B19 infection. Intern Med. 2002;41(4):295–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med. 1989;149(5):1153–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Krygier DS, Steinbrecher UP, Petric M, Erb SR, Chung SW, Scudamore CH, et al. Parvovirus B19 induced hepatic failure in an adult requiring liver transplantation. World J Gastroenterol. 2009;15(32):4067–9.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Anderson MJ, Jones SE, Fisher-Hoch SP, Lewis E, Hall SM, Bartlett CL, et al. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet. 1983;1(8338):1378.PubMedCrossRefGoogle Scholar
  91. 91.
    Naides SJ. Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin N Am. 1998;24(2):375–401.CrossRefGoogle Scholar
  92. 92.
    Scroggie DA, Carpenter MT, Cooper RI, Higgs JB. Parvovirus arthropathy outbreak in southwestern United States. J Rheumatol. 2000;27(10):2444–8.PubMedGoogle Scholar
  93. 93.
    Anderson LJ, Hurwitz ES. Human parvovirus B19 and pregnancy. Clin Perinatol. 1988;15(2):273–86.PubMedCrossRefGoogle Scholar
  94. 94.
    Beske F, Modrow S, Sorensen J, Schmidt H, Kriener S, Allwinn R, et al. Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40(1):89–91.PubMedCrossRefGoogle Scholar
  95. 95.
    Cavallo R, Merlino C, Re D, Bollero C, Bergallo M, Lembo D, et al. B19 virus infection in renal transplant recipients. J Clin Virol. 2003;26(3):361–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis. 2006;43(1):40–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Laurenz M, Winkelmann B, Roigas J, Zimmering M, Querfeld U, Muller D. Severe parvovirus B19 encephalitis after renal transplantation. Pediatr Transplant. 2006;10(8):978–81.PubMedCrossRefGoogle Scholar
  98. 98.
    Ardalan MR, Shoja MM, Tubbs RS, Esmaili H, Keyvani H. Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus b19 infection. Am J Transplant. 2008;8(6):1340–4.PubMedCrossRefGoogle Scholar
  99. 99.
    Egbuna O, Zand MS, Arbini A, Menegus M, Taylor J. A cluster of parvovirus B19 infections in renal transplant recipients: a prospective case series and review of the literature. Am J Transplant. 2006;6(1):225–31.PubMedCrossRefGoogle Scholar
  100. 100.
    Breinholt JP, Moulik M, Dreyer WJ, Denfield SW, Kim JJ, Jefferies JL, et al. Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. J Heart Lung Transplant. 2010;29(7):739–46.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Donoso Mantke O, Meyer R, Prosch S, Nitsche A, Leitmeyer K, Kallies R, et al. High prevalence of cardiotropic viruses in myocardial tissue from explanted hearts of heart transplant recipients and heart donors: a 3-year retrospective study from a German patients’ pool. J Heart Lung Transplant. 2005;24(10):1632–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Kuhl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005;112(13):1965–70.PubMedCrossRefGoogle Scholar
  103. 103.
    Jonetzko P, Graziadei I, Nachbaur K, Vogel W, Pankuweit S, Zwick R, et al. Fatal course of parvovirus B19-associated myocarditis in a female liver transplant recipient. Liver Transpl. 2005;11(4):463–6.PubMedCrossRefGoogle Scholar
  104. 104.
    Lee PC, Hung CJ, Lei HY, Chang TT, Wang JR, Jan MS. Parvovirus B19-related acute hepatitis in an immunosuppressed kidney transplant. Nephrol Dial Transplant. 2000;15(9):1486–8.PubMedCrossRefGoogle Scholar
  105. 105.
    Muetherig A, Christopeit M, Muller LP, Grothe W, Weber T, Theurich S, et al. Human parvovirus B19 infection with GvHD-like erythema in two allogeneic stem cell transplant recipients. Bone Marrow Transplant. 2007;39(5):315–6.PubMedCrossRefGoogle Scholar
  106. 106.
    Klumpen HJ, Petersen EJ, Verdonck LF. Severe multiorgan failure after parvovirus B19 infection in an allogeneic stem cell transplant recipient. Bone Marrow Transplant. 2004;34(5):469–70.PubMedCrossRefGoogle Scholar
  107. 107.
    Barzon L, Murer L, Pacenti M, Biasolo MA, Della Vella M, Benetti E, et al. Investigation of intrarenal viral infections in kidney transplant recipients unveils an association between parvovirus B19 and chronic allograft injury. J Infect Dis. 2009;199(3):372–80.PubMedCrossRefGoogle Scholar
  108. 108.
    Bultmann BD, Klingel K, Sotlar K, Bock CT, Baba HA, Sauter M, et al. Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum Pathol. 2003;34(1):92–5.PubMedCrossRefGoogle Scholar
  109. 109.
    Gallinella G, Manaresi E, Venturoli S, Grazi GL, Musiani M, Zerbini M. Occurrence and clinical role of active parvovirus B19 infection in transplant recipients. Eur J Clin Microbiol Infect Dis. 1999;18(11):811–3.PubMedCrossRefGoogle Scholar
  110. 110.
    Eid AJ, Posfay-Barbe KM. Parvovirus B19 in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S147–50.PubMedCrossRefGoogle Scholar
  111. 111.
    Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis. 2009;48(12):1713–23.PubMedCrossRefGoogle Scholar
  112. 112.
    Koch WC, Adler SP. Detection of human parvovirus B19 DNA by using the polymerase chain reaction. J Clin Microbiol. 1990;28(1):65–9.PubMedPubMedCentralGoogle Scholar
  113. 113.
    Park JB, Kim DJ, Woo SY, Choi GS, Chun JM, Jung GO, et al. Clinical implications of quantitative real time-polymerase chain reaction of parvovirus B19 in kidney transplant recipients - a prospective study. Transpl Int. 2009;22(4):455–62.PubMedCrossRefGoogle Scholar
  114. 114.
    Kumar J, Shaver MJ, Abul-Ezz S. Long-term remission of recurrent parvovirus-B associated anemia in a renal transplant recipient induced by treatment with immunoglobulin and positive seroconversion. Transpl Infect Dis. 2005;7(1):30–3.PubMedCrossRefGoogle Scholar
  115. 115.
    Florea AV, Ionescu DN, Melhem MF. Parvovirus B19 infection in the immunocompromised host. Arch Pathol Lab Med. 2007;131(5):799–804.PubMedGoogle Scholar
  116. 116.
    Mortimer PP, Humphries RK, Moore JG, Purcell RH, Young NS. A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature. 1983;302(5907):426–9.PubMedCrossRefGoogle Scholar
  117. 117.
    Corbett TJ, Saw H, Popat U, MacMahon E, Cohen BJ, Knowles WA, et al. Successful treatment of parvovirus B19 infection and red cell aplasia occurring after an allogeneic bone marrow transplant. Bone Marrow Transplant. 1995;16(5):711–3.PubMedGoogle Scholar
  118. 118.
    Frickhofen N, Abkowitz JL, Safford M, Berry JM, Antunez-de-Mayolo J, Astrow A, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990;113(12):926–33.PubMedCrossRefGoogle Scholar
  119. 119.
    Moudgil A, Shidban H, Nast CC, Bagga A, Aswad S, Graham SL, et al. Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation. 1997;64(12):1847–50.PubMedCrossRefGoogle Scholar
  120. 120.
    Azzi A, Fanci R, Ciappi S, Zakrzewska K, Bosi A. Human parvovirus B19 infection in bone marrow transplantation patients. Am J Hematol. 1993;44(3):207–9.PubMedCrossRefGoogle Scholar
  121. 121.
    Arribas JR, Pena JM, Echevarria JE. Parvovirus B19-related anemia in an HIV-infected patient: rapid control after production of neutralizing antibodies during highly active antiretroviral therapy. Ann Intern Med. 2000;132(12):1011.PubMedCrossRefGoogle Scholar
  122. 122.
    Chen MY, Hung CC, Fang CT, Hsieh SM. Reconstituted immunity against persistent parvovirus B19 infection in a patient with acquired immunodeficiency syndrome after highly active antiretroviral therapy. Clin Infect Dis. 2001;32(9):1361–5.PubMedCrossRefGoogle Scholar
  123. 123.
    Ware AJ, Moore T. Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2001;32(7):E122–3.PubMedCrossRefGoogle Scholar
  124. 124.
    Bernstein DI, El Sahly HM, Keitel WA, Wolff M, Simone G, Segawa C, et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011;29(43):7357–63.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Bell LM, Naides SJ, Stoffman P, Hodinka RL, Plotkin SA. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med. 1989;321(8):485–91.PubMedCrossRefGoogle Scholar
  126. 126.
    Lui SL, Luk WK, Cheung CY, Chan TM, Lai KN, Peiris JS. Nosocomial outbreak of parvovirus B19 infection in a renal transplant unit. Transplantation. 2001;71(1):59–64.PubMedCrossRefGoogle Scholar
  127. 127.
    Seng C, Watkins P, Morse D, Barrett SP, Zambon M, Andrews N, et al. Parvovirus B19 outbreak on an adult ward. Epidemiol Infect. 1994;113(2):345–53.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007;35(10 Suppl 2):S65–164.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Oregon Health and Science University, Division of Infectious DiseasesPortlandUSA

Personalised recommendations